-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

Benzinga·05/20/2026 17:28:13
Listen to the news
Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Overweight and raises the price target from $190 to $220.